|
|
|
Another look needed! PCSK9 Forum educational slide resource programme
Educational resources are an essential component of the mission of PCSK9 Forum to inform about PCSK9 science and therapeutics. Consistent with this mission, PCSK9 Forum launched an innovative expert-led educational slide resource programme. Now is the time to review this series of slide resources, covering both clinical trials and critical background to PCSK9.
|
 |
What does this slide resource programme cover?
The programme provides a concise overview of key trials, with expert interpretation in accompanying videos from the PCSK9 Forum Editorial Board.
Check out the slide resources for:
- FOURIER AND ODYSSEY - landmark trials for PCSK9 inhibition. Key analyses from these trials, including:
- In FOURIER: evolocumab in peripheral artery disease, and influence of the severity and extent of coronary artery disease on clinical benefit
- In ODYSSEY OUTCOMES: impact of alirocumab on total cardiovascular events
- ODYSSEY-DM Insulin trial: alirocumab in type 1 and type 2 diabetes
- Inclisiran and the ORION clinical development program – the next approach to PCSK9 inhibition
|
What about background to PCSK9?
Beyond the trials, supporting slide resources address key questions about PCSK9:
- Why do LDL cholesterol levels need to be lower?
- Why is PCSK9 a key therapeutic target?
- Why is immunotherapy an attractive approach to managing hypercholesterolaemia?
- What are the current approaches to targeting PCSK9?
|
This comprehensive programme provides accessible resources for busy clinicians in their routine practice. So, take another look, download these free resources and share them with your colleagues now.
Download here » |
|
|
For the latest updates, PCSK9 news and analysis. |
|
Hot topics, news and conference reports. |
|
For videos, interviews and webcasts from leading experts. |
|
|
|
|
|
